Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.

Front Endocrinol (Lausanne) · 2022 · PMC8908261 · PMID 35282455

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Our results indicated that empagliflozin could enhance insulin sensitivity, as measured by HOMA-IR and HOMA2-IR, though the differences did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.